List of Astepro Allergy drug patents

Astepro Allergy is owned by Bayer Hlthcare.

Astepro Allergy contains Azelastine Hydrochloride.

Astepro Allergy has a total of 3 drug patents out of which 0 drug patents have expired.

Astepro Allergy was authorised for market use on 17 June, 2021.

Astepro Allergy is available in spray, metered;nasal dosage forms.

Astepro Allergy can be used as otc use: allergy symptom reliever; temporary relief of these symptoms due to hay fever or other upper respiratory allergies: nasal congestion, runny nose, sneezing and itchy nose.

The generics of Astepro Allergy are possible to be released after 04 June, 2028.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8518919 BAYER HLTHCARE Compositions comprising azelastine and methods of use thereof
Nov, 2025

(2 years from now)

US9919050 BAYER HLTHCARE Compositions comprising azelastine
Nov, 2025

(2 years from now)

US8071073 BAYER HLTHCARE Compositions comprising azelastine and methods of use thereof
Jun, 2028

(5 years from now)

Drugs and Companies using AZELASTINE HYDROCHLORIDE ingredient

Market Authorisation Date: 17 June, 2021

Treatment: Otc use: allergy symptom reliever; Temporary relief of these symptoms due to hay fever or other upper respiratory allergies: nasal congestion, runny nose, sneezing and itchy nose

Dosage: SPRAY, METERED;NASAL

How can I launch a generic of ASTEPRO ALLERGY before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in